The purpose of this study was to determine the in situ distribution of PCR-amplified HIV-1 and EBV DNA in hyperplastic lymph nodes and in AIDS-related lymphomas. PCRamplified HIV-1 DNA was detected, on average, in about 30% and 20% of the CD4 and CD21 dendritic cells, respectively, in and around the expanded gennrnal centers of hyperplastic lymph nodes in seropositive, asymptomatic people. PCR-amplified EBV DNA was noted, on average, in about 20% of U6 B-cells. The amplified HIV-1 DNA was noted in rare non-neoplastic cells in five AIDS-related lymphomas; the other three cases were negative for the viral DNA. Amplified EBV DNA was detected in five of eight lymphomas ' but in only three of these tissues did the viral DNA localize to the malignant cells. We condude that although many cells in hyperplastic lymph nodes from people with early HIV-1 infection contain W -1 and EBV DNA, these viruses are often absent in the malignant cells of AIDStelated lymphoma. This suggests that although infection by these viruses and the concomitant lymphoid hyperplasia may predispose to lymphoma, the viruses are not required for maintenance of the malignant phenotype. ( J Hisrochem Cytochem 44: 1085-1089, 19%) KEY WORDS: HIV-1; EBV Lymphoma; In situ PCR.
Introduction
Infection with the human immunodeficiency virus (HIV-1) has been related to an increased risk for development of lymphomas. About 90% of these AIDS-related lymphomas are high-grade lesions, either large-cell immunoblastic, Burkitt's, or diffuse small non-cleaved cell type (Beral et al., 1991) .
A model for immunosuppression-related lymphomas can be seen in post-transplant lymphoproliferative disorder, which presents as a spectrum of disease ranging from lymphoid hyperplasia to overt high grade malignancy. Analysis of these lesions has shown evidence of active Epstein-Barr virus (EBV) infection in many of the cases (Craig et al., 1993) . Studies of lymphomas in patients without overt immunosuppression has demonstrated that EBV DNA may be present, with detection rates that vary from <lo% to near 100% . Although EBV is postulated to have a role in AIDSrelated lymphomas, HIV-1 itself has also been implicated in the evolution of these lymphoid malignancies. HIV-1 can cause effects in vitro that are similar to those attributed to EBV, including poly-clonal B-cell activation and the transformation and immortalization of cell lines (Lawrence and Astrin, 1991) .
Although EBV and HIV-1 have both been implicated in the genesis of AIDS-related lymphomas, it is unclear what specific role either of these viruses may play in the evolution and maintenance of these tumors. In a prior study of HIV-1 in seropositive, asymptomatic people and in AIDS patients without lymphoid malignancies, we showed HIV-1 DNA to be present in all lymph nodes, primarily in CD4 and CD21 dendritic cells (Nuovo et al., 1994) . In this report we extend our analyses of the hyperplastic lymph nodes to EBV and determine the histologic distribution of these two viruses in AIDS-related lymphomas.
Materials and Methods
Case Selection. Eight lymphomas from patients with AIDS were identified from the files of University Hospital. Stony Brook. The six hyperplastic lymph nodes from seropositive, asymptomatic patients were part of a study approved by the hospital's institutional review board and included written informed consent. Control cells for EBV included the Raji cell line and peripheral leukocytes from a person with no history of EBV infection. Control cells for the analysis of HIV-1 infection were pooled, normal lymphocytes either infected with HIV-1 IIIB or sham-infected. as previously described (Nuovo et al., 1994) . All material was fixed in 10% buffered formalin.
Standard In Situ Hybridization. Standard in situ hybridization analysis was done for sequences homologous to EBV and HIV-1 DNA. The probes used for HIV-1 detection were SK19 (42 BP) and SK102 (33 BP) (Perkin-Elmer Corporation; Norwalk, CT) which correspond to the gag region. The probe used for EBV detection, TC 62 (15 BP). corresponds to the BamHI internal repeat region 1, usually present as about 10 copies per cell. The standard in situ hybridization protocol used for these digoxigenin-labeled oligoprobes has been previously published (Nuovo, 1996; Nuovo et al.. 1994) .
A hybridization signal is evident as a dark blue precipitate (NBT-BCIP chromogen), whereas the counterstain nuclear Fast red stains nuclei and cytoplasm pale pink.
PCR In Situ Hybridization. Detection of PCR-amplified HIV-1 DNA was done according to our previously published protocol (Nuovo, 1996; Nuovo et al., 1994) . The primers SK38 and SK39 plus SK145 and SK431 are used with the probes SK19 and SK102, respectively, for detection of HIV-1. The primers used for amplification of the EBV genome are TC60 and TC61. With every slide, a negative control in which the Taq polymerase was omitted was performed. Additional negative controls included an overnight pretreatment in DNAse before PCR as well as the use of human papillomavirus (HPV)-related primers in the PCR step. HPV does not infect lymphoid tissue
To determine if infection by HIV-1 was activated with associated viral transcripts, reverse transcriptase (RT) in situ PCR was performed. The procedure for RT in situ PCR has three modifications. (a) After protease digestion the tissue is treated overnight in an RNAse-free DNAse solution (Boehringer Mannheim, Indianapolis, IN; 10 Uisection at 37°C). which eliminates nonspecific mis-priming and DNA repair. (b) RT employing the downstream primer (SK 39 or SK 431) is done at 42°C for 30 min according to the manufacturer's recommendations (Perkin-Elmer). (c) Direct incorporation of digoxigenin-dUTP into the PCR product is accomplished by using 10 pM of the reporter molecule in the amplifying solution. Additional controls for the specificity of the signal with RT in situ PCR included the use of non-sense (HPV-specific) primers and the omission of the primer during the RT step.
Solution-phase PCR. Solution-phase PCR was performed by a previously described protocol (Nuovo. 1996) . using the hot-start maneuver with direct incorporation of i2P-labeled dCTP. The autoradiograph was examined for the expected bands of 115 BP for HIV-1 and 160 BP for EBV.
Immunohistochemistry. Sections were analyzed with mouse monoclonal antibodies directed to either CD4 (T-helper cells), CD21 (follicular dendritic cells), or L26 (pan-B-cells) (each from Dako, Carpinteria, CA). For CD21 and CD4 the dilution was 1:10 and for L-26 the dilution was 1:400. The antigen-antibody complex was detected according to previously published protocol (Nuovo et al., 1994) .
Results
A total of 14 tissues were analyzed in this study. Six tissues were hyperplastic lymph nodes form HIV-1 seropositive, asymptomatic people and t h e other eight were lymphomas. T h e six lymph nodes exhibited marked expansion of the germinal centers a n d parafollicular zones, with focal dissolution of the mantle zones. The histologic features of the eight lymphomas are listed in Table 1 .
Solution-phase PCR for sequences homologous to EBV and HIV-1 DNA was first performed o n each of the 14 tissues. PCRamplified EBV DNA was detected in 4 / 8 (50%) of t h e lymphomas and 4/6 (67%) of the hyperplastic lymph nodes. PCR-amplified HIV-1 DNA was detected in 518 (63%) of the lymphomas and 6/6 (100%) of the hyperplastic lymph nodes.
To ascertain which cell type(s) contained HIV-1 DNA, in situ hybridization and PCR in situ hybridization were performed o n each of the 14 tissues. Standard in situ hybridization revealed the provirus in two of six of the hyperplastic lymph nodes a n d did not detect HIV-1 DNA in any of the eight lymphomas. Only rare positive cells in the germinal center and parafollicular zones were identified in t h e former two tissues. After PCR amplification, HIV-1 DNA was detected in six of eight of t h e lymphomas (Table 1 ) and in each of the six hyperplastic lymph nodes (Table 2; Figure 1 ). Although PCR-amplified HIV-I DNA was detected in six of eight lymphomas, it was of interest that usually only rare benign cells interspersed among the tumor were positive. Importantly, PCRamplified HIV-1 DNA was not identified in the lymphoma cells ( Figure 1 ). Although HIV-1 DNA was not evident in the Reed-Sternberg cells of the Hodgkin's lymphoma cases (Cases 1 and 2 , Table 1 ). HIV-1 infection was evident in scattered atypical lymphocytes in those cases that did co-label with C D 4 (data not shown).
The hybridization signal in the positive cases was eliminated by predigestion in DNAse, by omission of the Taq polymerase, or by the use of the nonspecific HPV primers in the PCR step (data not shown). Similarly, the signal was evident in t h e lymphocytes infected by HIV-1 b u t not in t h e sham-infected cells. To determine if the HIV-1 infection was activated or latent, the positive cases were analyzed by RT in situ PCR for transcripts corresponding to the gag region a n d multiple spliced transcripts from the tat and rev exons, as previously described (Nuovo et al., 1994) . In t h e six lymphomas that contained HIV-1 D N A , four had detectable viral transcripts in proportions similar to that noted for HIV-I D N A . The The CD4 cells localized to the germinal centers and parafollicular areas. HIV-1 + CD4 cellsitotal CD4 cell ratios were determined in the same manner as described detection rate of HIV-1 RNA was very variable in the hyperplastic lymph nodes, ranging from less than 5% to about 80% of the HIV-1 DNA-positive cells (Nuovo et al., 1994) .
In situ hybridization analysis of EBV yielded a detection rate of 2/8 for the lymphomas and 216 for the hyperplastic lymph nodes. Only rare positive cells were identified by standard in situ analysis. The detection rate for EBV DNA increased to 5/8 for the lymphomas (Table 1) and 5/6 for the hyperplastic lymph nodes (Table 2) when in situ hybridization was preceded by PCR. The EBV-positive cells in lymphoma Cases 1 and 7 were scattered, benign lymphocytes. In Cases 3, 6, and 8, 10-70% of the malignant cells contained PCR-amplified EBV DNA (Figure l) , as well as occasional benign lymphocytes. On average, a greater proportion of benign lymphocytes were infected by EBV in the hyperplastic lymph nodes, as determined by PCR in situ hybridization. The infected cells localized to the area of the mantle zone and the germinal center; this is the same distribution as for the pan-B-cell marker L26. Analysis of serial sections studied by immunohistochemistry for L26 and for EBV DNA by PCR in situ hybridization showed that, on average, about 20% of cells from the L26-rich areas were EBV-positive (Table 2; Figure 1 ). The hybridization signal in the positive cases was eliminated by predigestion in DNAse, by omission of the Taq polymerase, or by the use of the nonspecific HPV primers (data not shown). Similarly, the signal was evident in the Raji cells after in situ amplification but not in normal, noninfected peripheral blood mononuclear cells (data not shown).
As noted, solution-phase PCR revealed EBV DNA in 8/14 tissues, whereas PCR in situ hybridization yielded a detection rate of 10/14 for EBV. In 10 cases there was concordance between the solution phase and in situ PCR assays, whereas in three tissues solution-phase PCR was negative for EBV, while the virus was detected in rare cells in the corresponding tissue by in situ PCR and in the other case the virus was detected by solution-phase PCR and not by in situ PCR. For HIV-1, solution-phase PCR revealed the provirus in 11/ 14 tissues, whereas PCR in situ hybridization yielded a detection rate of 12/14. In 11 cases there was concordance between the solution-phase and in situ PCR assays, whereas in two tissues solution-phase PCR was negative for HIV-1 while the virus was detected in rare cells in the corresponding tissue by in situ PCR and in the other case the virus was detected by solution-phase PCR and not by in situ PCR.
Discussion
This study examined the detection rates and histological distribution of EBV and HIV-1 DNA in hyperplastic lymph nodes from people infected with HIV-1 but who had no symptoms of AIDS. Each of the six hyperplastic lymph nodes contained HIV-1 and 516 of these tissues contained EBV DNA, as determined by PCR in situ hybridization. On average, about 20-30% of the target cells (CD21 and CD4 for HIV-1 and L26 for EBV) were infected. The detection rate was much lower with standard in situ hybridization. The greater detection rate of PCR in situ hybridization vs standard in situ hybridization noted in this study for HIV-1 is similar to that reported in several other studies, and is consistent with the low copy number of the provirus (Nuovo, 1996; Nuovo et al.. 1994) . It is not surprising that a similar enhancement in the detection rate was noted for EBV, because the internal repeat sequence target is often present in about 10 copies, which is near the limit of standard in situ analysis, and this study employed a small 15-mer internal oligoprobe that has poorer sensitivity compared to the larger (100-200 BP) probes (Nuovo, 1996) . These results demonstrate that infection by these viruses is common and widespread in the hyperplastic lymph nodes that presage AIDS, and strongly suggests the the activity of HIV-1 and EBV in the CD4 plus CD21 follicular dendritic cells and the L26 B-cells, respectively, is in part responsible for the dramatic hyperplastic histological changes.
Amplified HIV-1 and EBV DNA were detected in relatively few of the benign lymphocytes present in the lymphomas. In the lymphomas that were HIV-1-positive, only the surrounding normal cells had detectable virus. Although malignant lymphocytes that contained EBV were detected in abundance in three cases, in five of the eight cases the malignant cells did not have detectable PCRamplified EBV DNA. The reported detection rate of EBV in lymphomas is highly variable. Using in situ hybridization, Hui et al. (1994) detected EBV DNA in 11/11 gastric lymphomas, whereas Chan et al. (1994) noted that 0120 B-cell lymphomas of the tongue region were EBV-positive using the same methodology. The reason(s) for this marked variability in detection rates of EBV in lymphomas requires further study. However, we can speculate that it may reflect the fact that EBV is a common co-factor for development of malignant lymphoid lesions but is not essential for maintenance of the malignant phenotype. If we assume that the subclones of tumor cells that are EBV-negative have an equal advantage in malignant propensity compared to the EBV-positive subclones, then this could explain, in part, the finding in this study that some lymphomas contained EBV-positive and EBV-negative malignant cells, whereas others did not contain PCR-amplified EBV DNA. Although HIV-1 does have the ability to induce T-and B-cell hyperplasia in vitro, this study did not detect HIV-1 DNA in any malignant cells. Whether this means that integrated HIV-1 DNA inhibits the development of the malignant phenotype in lymphocytes or that lymphoma cells which contain the provirus are at a disadvantage in their growth parameters vs the HIV-1-negative malignant subclones requires further study.
To our knowledge, this is the first report to analyze the histological distribution of PCR-amplified EBV DNA in hyperplastic lymph nodes from HIV-1-positive patients and AIDS-related lymphomas and to compare this to standard in situ hybridization. Lin et al. (1994) did report on the detection of EBV DNA in nasopharyngeal carcinomas and cell lines using in situ hybridization and PCR in situ hybridization, and noted an increased signal in their Raji cell line, as also noted in this study.
Whether the virus-related lymph node hyperplasia is, in part, responsible for the increased incidence of lymphoma in AIDS patients will require further study but is a tenable hypothesis. In this sense, it is analogous to the precancerous, well-characterized condition in the uterine cervix that is invariably associated with infection by HPV, typically type 16. However, it has been well documented that HPV transcription of certain open reading frame, such as E6 and E7, is a critical aspect of the malignant transformation and maintenance of the malignant phenotype in cervical cancer (Nuovo, 1994) . The data reported in this study suggest that continued viral presence is not obligatory in AIDS-related lymphomas. This is consistent with the recent study of Lin et al. (1994) . In that study, the authors demonstrated that EBV-positive nasopharyngeal carcinomas contained malignant cells that were negative for the virus, even with in situ PCR, and that the EBV-positive malignant cells were lost with increased passage when the cells were grown in tissue culture. Whether the ubiquitous EBV and HIV-1 infection that characterized the hyperplastic lymph nodes in people with early HIV-1 infection is needed to induce certain host DNA or transcriptional changes that are required for the evolution and maintenance of the malignant phenotype in AIDS-related lymphomas will require further study.
